The European Medicines Agency (EMEA) has made a recommendation to the European Commission (EC) for suspending Acomplia’s marketing authorization temporarily for the treatment of obese patients. The regulatory body concluded that the risks of Acomplia outweigh its benefits. Side effects such as depression have been a part of the warnings ever since the product was authorized in 2006. Sanofi-aventis is complying with the order, but believes that its product will continue to be an effective treatment.